AnalystsInsight

Doug Schenkel (UBS): Analyst Track Record and Price‑Target Accuracy

Doug Schenkel is one of the top‑ranked analysts in Exent’s 7‑year backtest. What Doug covers, how Doug’s ratings lean, how fast price targets were reached and the ratings from before the last 30 days; the full record and the newest calls are members‑only.

Published Updated 2 min readHow we research

What changed since Oct 12

Exent re-checks this page every day. Ratings appear 30 days after they are published; live calls are in Gems.

+2 new ratings (stocks members‑only)+2 stocks newly covered

Key takeaways

  • Doug Schenkel ranks among the top 50 healthcare analysts in Exent’s ranking, scored on a 7‑year backtest.
  • The exact rank, price‑target hit rate and live calls are members‑only in Exent Gems.
  • Doug published 3 ratings in the last 30 days, the latest on Oct 14, 2026.
  • Most‑covered stocks: ILMN, A, TXG, TMO.
  • In the past year Doug’s ratings were 52% Buy, 48% Hold and 0% Sell.

Doug Schenkel’s track record at a glance

Doug Schenkel of UBS ranks among the top 50 healthcare analysts in Exent’s ranking, with a focus on healthcare. The top of the ranking is what Exent Gems follows, so Doug’s exact rank, hit rate and live calls are for members.

MetricDoug SchenkelAll analysts
Exent rank—
Price‑target hit rate53.6%
Calls up after 12 months64.6%
Median 12‑month return of calls+13.4%
Median days to hit target91 days
Stocks covered39—

How fast price targets were reached

Time to reach the targetDoug Schenkel
Under 30 days30.5%
30–90 days30.0%
90–180 days22.3%
Over 180 days17.3%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Doug Schenkel covers most

ILMN · A · TXG · TMO · DHR · WAT · DXCM · MYGN

In the past year Doug’s ratings were 52% Buy, 48% Hold and 0% Sell.

Doug Schenkel’s latest ratings

DateStockActionRatingPrice target
Oct 14, 2026
Oct 2, 2026
Sep 29, 2026
Sep 13, 2026DHRInitiated Coverage: BuyBuy$250.00
Sep 13, 2026GRALInitiated Coverage: BuyBuy$105.00
Sep 9, 2026LON-VTYInitiated Coverage: HoldHold$300.00
Sep 9, 2026DHRInitiated Coverage: BuyBuy$250.00
Sep 9, 2026WATUpgraded: BuyBuy$490.00
Sep 9, 2026WSTReiterated: BuyBuy$415.00
Sep 9, 2026ILMNUpgraded: BuyBuy$260.00
Sep 9, 2026VCYTReiterated: BuyBuy$65.00
Sep 9, 2026RGENReiterated: BuyBuy$225.00
Sep 9, 2026GRALInitiated Coverage: BuyBuy$105.00
Sep 9, 2026NTRAReiterated: BuyBuy$435.00
Sep 9, 2026GHReiterated: BuyBuy$225.00
  • Oct 14, 2026
    Stock
    Action
    Rating
    Price target
  • Oct 2, 2026
    Stock
    Action
    Rating
    Price target
  • Sep 29, 2026
    Stock
    Action
    Rating
    Price target
  • Sep 13, 2026
    Stock
    DHR
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $250.00
  • Sep 13, 2026
    Stock
    GRAL
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $105.00
  • Sep 9, 2026
    Stock
    LON-VTY
    Action
    Initiated Coverage: Hold
    Rating
    Hold
    Price target
    $300.00
  • Sep 9, 2026
    Stock
    DHR
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $250.00
  • Sep 9, 2026
    Stock
    WAT
    Action
    Upgraded: Buy
    Rating
    Buy
    Price target
    $490.00
  • Sep 9, 2026
    Stock
    WST
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $415.00
  • Sep 9, 2026
    Stock
    ILMN
    Action
    Upgraded: Buy
    Rating
    Buy
    Price target
    $260.00
  • Sep 9, 2026
    Stock
    VCYT
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $65.00
  • Sep 9, 2026
    Stock
    RGEN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $225.00
  • Sep 9, 2026
    Stock
    GRAL
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $105.00
  • Sep 9, 2026
    Stock
    NTRA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $435.00
  • Sep 9, 2026
    Stock
    GH
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $225.00

Doug published 3 ratings in the last 30 days, the latest on Oct 14, 2026. Ratings from the last 30 days are members‑only in Exent Gems, with the stocks where several top‑ranked analysts agree; older ratings are shown in full.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Oct 20, 2026; ranking updated Oct 21, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Doug Schenkel’s full record and latest ratings, without the 30‑day delay.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring, Doug Schenkel ranks among the top 50 healthcare analysts in Exent’s ranking, based on a 7-year backtest of price-target hit rate, returns after calls and number of ratings. The exact rank, hit rate and live calls are members-only in Exent Gems (exent.ai/radar). Past accuracy does not guarantee future accuracy.

Doug Schenkel’s price-target hit rate is part of the members-only record in Exent Gems (exent.ai/radar). For comparison, the average analyst’s price targets were reached 53.6% of the time.

Doug Schenkel (UBS) covers 39 stocks, mostly in healthcare. The most frequently rated are ILMN, A, TXG, TMO, DHR.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.